Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma
Radiation-induced sarcomas in the brain are extremely rare, usually occur with an average latency of 9 years, and are associated with poor outcomes. Latency periods shorter than 1 year may indicate a genetic predisposition such as Li-Fraumeni syndrome. A 34-year-old man underwent initial tumor resec...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2019/7950782 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564702577688576 |
|---|---|
| author | Richard A. Peterson Bhavani Kashyap Pamala A. Pawloski Anna C. Forsberg Leah R. Hanson |
| author_facet | Richard A. Peterson Bhavani Kashyap Pamala A. Pawloski Anna C. Forsberg Leah R. Hanson |
| author_sort | Richard A. Peterson |
| collection | DOAJ |
| description | Radiation-induced sarcomas in the brain are extremely rare, usually occur with an average latency of 9 years, and are associated with poor outcomes. Latency periods shorter than 1 year may indicate a genetic predisposition such as Li-Fraumeni syndrome. A 34-year-old man underwent initial tumor resection and radiation therapy for a World Health Organization (WHO) Grade II Astrocytoma. Within 6 months, the tumor recurred as WHO Grade III and was treated with temozolomide and then bevacizumab. Despite the patient’s apparent improving condition, MRI revealed new dural-based lesions 10 months after radiation therapy and identified as high-grade sarcoma. The patient resumed bevacizumab, began NovoTTF treatment for progressing glioma, and ifosfamide/doxorubicin for the sarcoma. Genetic testing revealed no pathogenic mutation in the TP53 gene. Ultimately, treatment was unsuccessful and the patient succumbed to glioma and sarcoma within 2 years of initial diagnosis. This case was unique due to the rapidly progressing glioma and sudden appearance of a high-grade sarcoma. It is unusual to have two separate intracranial primary cancers with each requiring a different chemotherapy regimen. We discuss the difficulty of simultaneously treating with separate chemotherapy regimens. It remains unclear whether the sarcoma was induced by the radiation treatment or a genetic predisposition. |
| format | Article |
| id | doaj-art-a82db6f62be740c58812c1fbf08d7387 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-a82db6f62be740c58812c1fbf08d73872025-02-03T01:10:21ZengWileyCase Reports in Oncological Medicine2090-67062090-67142019-01-01201910.1155/2019/79507827950782Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal GliomaRichard A. Peterson0Bhavani Kashyap1Pamala A. Pawloski2Anna C. Forsberg3Leah R. Hanson4Regions Hospital Cancer Care Center, St Paul, MN, USAHealthPartners Neuroscience Center, St Paul, MN, USAHealthPartners Institute, Minneapolis, MN, USAHealthPartners Neuroscience Center, St Paul, MN, USAHealthPartners Neuroscience Center, St Paul, MN, USARadiation-induced sarcomas in the brain are extremely rare, usually occur with an average latency of 9 years, and are associated with poor outcomes. Latency periods shorter than 1 year may indicate a genetic predisposition such as Li-Fraumeni syndrome. A 34-year-old man underwent initial tumor resection and radiation therapy for a World Health Organization (WHO) Grade II Astrocytoma. Within 6 months, the tumor recurred as WHO Grade III and was treated with temozolomide and then bevacizumab. Despite the patient’s apparent improving condition, MRI revealed new dural-based lesions 10 months after radiation therapy and identified as high-grade sarcoma. The patient resumed bevacizumab, began NovoTTF treatment for progressing glioma, and ifosfamide/doxorubicin for the sarcoma. Genetic testing revealed no pathogenic mutation in the TP53 gene. Ultimately, treatment was unsuccessful and the patient succumbed to glioma and sarcoma within 2 years of initial diagnosis. This case was unique due to the rapidly progressing glioma and sudden appearance of a high-grade sarcoma. It is unusual to have two separate intracranial primary cancers with each requiring a different chemotherapy regimen. We discuss the difficulty of simultaneously treating with separate chemotherapy regimens. It remains unclear whether the sarcoma was induced by the radiation treatment or a genetic predisposition.http://dx.doi.org/10.1155/2019/7950782 |
| spellingShingle | Richard A. Peterson Bhavani Kashyap Pamala A. Pawloski Anna C. Forsberg Leah R. Hanson Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma Case Reports in Oncological Medicine |
| title | Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma |
| title_full | Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma |
| title_fullStr | Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma |
| title_full_unstemmed | Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma |
| title_short | Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma |
| title_sort | unique case report of a meningeal sarcoma arising during ongoing treatment for progressing intraparenchymal glioma |
| url | http://dx.doi.org/10.1155/2019/7950782 |
| work_keys_str_mv | AT richardapeterson uniquecasereportofameningealsarcomaarisingduringongoingtreatmentforprogressingintraparenchymalglioma AT bhavanikashyap uniquecasereportofameningealsarcomaarisingduringongoingtreatmentforprogressingintraparenchymalglioma AT pamalaapawloski uniquecasereportofameningealsarcomaarisingduringongoingtreatmentforprogressingintraparenchymalglioma AT annacforsberg uniquecasereportofameningealsarcomaarisingduringongoingtreatmentforprogressingintraparenchymalglioma AT leahrhanson uniquecasereportofameningealsarcomaarisingduringongoingtreatmentforprogressingintraparenchymalglioma |